Genom ve Düzenlenmesi: Temel Kavramlar ve Tarihsel Gelişim

Goldman AD, Landweber LF. What Is a Genome? PLoS Genet. 2016;12(7):e1006181.

Zheng Y, Li Y, Zhou K, Li T, VanDusen NJ, Hua Y. Precise genome-editing in human diseases: mechanisms, strategies and applications. Signal Transduct Target Ther. 2024;9(1):47.

Carroll D. Genome Editing: Past, Present, and Future. Yale J Biol Med. 2017;90(4):653–659.

Cohen SN, Chang ACY, Boyer HW, Helling RB. Construction of Biologically Functional Ba- cterial Plasmids In Vitro. Proc Natl Acad Sci USA. 1973;70(11):3240–3244.

Jackson DA, Symons RH, Berg P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40. Proc Natl Acad Sci USA. 1972;69(10):2904–2909.

Institute of Medicine. Asilomar and Recombinant DNA: The End of the Beginning. In: Bio- medical Politics. Washington, DC: National Academies Press; 1991.

National Academies of Sciences, Engineering, and Medicine. Biomedical Politics. Washing- ton, DC: National Academies Press; 1991.

Lu D, Searles MA, Klug A. Crystal structure of a zinc-finger-RNA complex reveals two modes of molecular recognition. Nature. 2003;426(6962):96–100.

Berg P, Baltimore D, Brenner S, Roblin RO, Singer MF. Summary statement of the Asilomar conference on recombinant DNA molecules. Proc Natl Acad Sci USA. 1975;72(6):1981–1984.

Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-direc- ted gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270(5235):475– 480.

Carroll D. Genome engineering with targetable nucleases. Annu Rev Biochem. 2014;83:409– 439.

Carroll D. Genome Engineering With Zinc-Finger Nucleases. Genetics. 2011;188(4):773–782.

Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385(6619):810–813.

Loi P, Czernik M, Zacchini F, Iuso D, Scapolo PA, Ptak G. Sheep: the first large animal model in nuclear transfer research. Cell Reprogram. 2013;15(5):367–373.

Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013;14(1):49–55.

Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing techno- logy in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5:1.

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmab- le Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012;337(6096):816–821.

Royal Swedish Academy of Sciences. The Nobel Prize in Chemistry 2020: Genetic scissors: A tool for rewriting the code of life [Internet]. Stockholm: Nobel Prize; 2020 [cited 2024 Dec 24]. Available from: https://www.nobelprize.org

Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420–424.

Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-repla- ce genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149– 157.

Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023;24(3):161–177.

Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for ge- nome engineering. Trends Biotechnol. 2013;31(7):397–40523. Gok ZG, Tunali BC. (CRISPR- Cas immun sisteminin biyolojisi, mekanizmasi ve kullanim alanlari. Int J Eng Res Dev. 2016;8(2)).

Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for ge- nome engineering. Trends Biotechnol. 2013;31(7):397–405.

Collier TC, Lee Y, Mathias DK, Marsden CD, Warner ME, Romero-Severson J, et al. CRISPR- Cas9 and Cas12a target site richness reflects genomic diversity in natural populations. BMC Genomics. 2024;25:700.

Yeadon J. Pros and cons of ZFNs, TALENs, and CRISPR/Cas [Internet]. 2014 Mar 4 [cited 2024 Dec 24]. Available from: https://www.jax.org

Guo T, Feng YL, Xiao JJ, Liu Q, Sun XN, Xiang JF, et al. Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing. Genome Biol. 2018;19:170.

Zhu L, Mon H, Xu J, Lee JM, Kusakabe T. CRISPR/Cas9-mediated knockout of factors in non-homologous end-joining pathway enhances gene targeting in silkworm cells. Sci Rep. 2016;5:18103.

Kurtoglu EL, Tekedereli I. DNA onarim mekanizmalari. Balikesir Saglik Bilimleri Dergisi. 2015;4(3):169.

Chen J, Potlapalli R, Quan H, Chen L, Xie Y, Pouriyeh S, et al. Exploring DNA'damage and Repair Mechanisms: A Review with Computational Insights. Biotech (Basel). 2024;13(1):3.

Gohil D, Sarker AH, Roy R. Base Excision Repair: Mechanisms and Impact in Biology, Dise- ase, and Medicine. Int J Mol Sci. 2023;24(18):14186.

Reardon JT, Sancar A. Nucleotide excision repair. Methods Enzymol. 2004;406:1–29.

Spivak G. Nucleotide excision repair in humans. DNA Repair (Amst). 2015;36:13–18.

Sfeir A, Symington LS. Microhomology-Mediated End Joining: A Back-up Survival Mecha- nism or Dedicated Pathway? Trends Biochem Sci. 2015;40(11):701–714.

Lu J, Wang S. CRISPR/Cas9-Mediated Gene Knockout in Cells and Tissues Using Lentivirus. Curr Protoc. 2023;3(5):e772.

Sivasubbu S, Balciunas D, Amsterdam A, Ekker SC. Insertional mutagenesis strategies in zeb- rafish. Genome Biol. 2007;8(Suppl 1):S9.

Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-Guided Human Genome Engineering via Cas9. Science. 2013;339(6121):823–826.

Zhou W, Yang J, Zhang Y, Hu X, Wang W. Current landscape of gene-editing techno- logy in biomedicine: Applications, advantages, challenges, and perspectives. MedComm. 2022;3(3):e155.

Phan HTL, Kim K, Lee H, Seong JK. Progress in and Prospects of Genome Editing Tools for Human Disease Model Development and Therapeutic Applications. Genes. 2023;14(2):483.

Rao Y, Yang X, Pan C, Wang C, Wang K. Advance of CRISPR-Cas9 System and Its Application in Crop Improvement. Front Plant Sci. 2022;13:839001.

Zhang ML, Li HB, Jin Y. Application and perspective of CRISPR/Cas9 genome editing tech- nology in human disease modeling and gene therapy. Front Genet. 2024;15:1364742.

Deneault E. Recent Therapeutic Gene Editing Applications to Genetic Disorders. Curr Issues Mol Biol. 2024;46(5):4147–4185.

Xu W, Zhang S, Qin H, Yao K. From bench to bedside: cutting-edge applications of base edi- ting and prime editing in precision medicine. J Transl Med. 2024;22(1):1133.

Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases. Signal Transduct Target Ther. 2020;5:1.

Kuhn A, Ackermann M, Mussolino C, Cathomen T, Lachmann N, Moritz T. TALEN-me- diated functional correction of human iPSC-derived macrophages in context of hereditary pulmonary alveolar proteinosis. Sci Rep. 2017;7(1):15195.

Alkanli SS, Alkanli N, Ay A, Albeniz I. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington’s Disease. Mol Neurobiol. 2023;60(3):1486–1498.

Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157.

Lopes R, Prasad MK. Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics. Front Bioeng Biotechnol. 2024;11.

Guo M, Ren K, Zhu Y, Tang Z, Li Y, Zhang B, et al. Structural insights into a high fidelity variant of SpCas9. Cell Res. 2019;29:183–192.

Tang H, Wang D, Shu Y. Structural insights into Cas9 mismatch: promising for development of high-fidelity Cas9 variants. Signal Transduct Target Ther. 2022;7:271.

Asmamaw Mengstie M, Teshome Azezew M, Asmamaw Dejenie T, Teshome AA, Tadele Ad- masu F, Behaile Teklemariam A, et al. Recent Advancements in Reducing the Off-Target Effe- ct of CRISPR-Cas9 Genome Editing. Biologics. 2024;18:21–28.

Singh M, Bindal G, Misra CS, Rath D. The era of Cas12 and Cas13 CRISPR-based disease diagnosis. Crit Rev Microbiol. 2022;48(6):714–729.

Kim Y, Kim N, Okafor I, Kim J, Jang G, Son S, et al. Sniper2L is a high-fidelity Cas9 variant with high activity. Nat Chem Biol. 2023;19:972–980.

Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, et al. A high-fi- delity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018;24(8):1216–1224.

Pedrazzoli E, Bianchi A, Umbach A, Amistadi S, Brusson M, Frati G, et al. An optimized SpCas9 high-fidelity variant for direct protein delivery. Mol Ther. 2023;31(7):2257–2265.

Wu X, Kriz AJ, Sharp PA. Target specificity of the CRISPR-Cas9 system. Quant Biol. 2014;2(2):59–70.

Tycko J, Myer VE, Hsu PD. Methods for Optimizing CRISPR-Cas9 Genome Editing Specifi- city. Mol Cell. 2016;63(3):355–370.

Lei T, Wang Y, Zhang Y, Yang Y, Chen J, Huang J, et al. Leveraging CRISPR gene editing te- chnology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024;38:2517–2543.

Sioson VA, Kim M, Joo J. Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine. Biomed Eng Lett. 2021;11(3):217–233.

Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med. 2021;4(3):179–191.

Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-rep- lace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–157.

Doman JL, Sousa AA, Randolph PB, Chen PJ, Liu DR. Designing and executing prime editing experiments in mammalian cells. Nat Protoc. 2022;17(11):2431–2468.

Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023;24(3):161–177.

Kantor A, McClements ME, MacLaren RE. CRISPR-Cas9 DNA Base-Editing and Prime-Edi- ting. Int J Mol Sci. 2020;21(17):6240.

Sakata RC, Ishiguro S, Mori H, Tanaka M, Tatsuno K, Ueda H, et al. Base editors for simulta- neous introduction of C-to-T and A-to-G mutations. Nat Biotechnol. 2020;38:865–869.

Yang L, Li H, Han Y, Song Y, Wei M, Fang M, et al. CRISPR/Cas9 Gene Editing System Can Alter Gene Expression and Induce DNA'damage Accumulation. Genes. 2023;14(4):806.

Hunt JMT, Samson CA, Rand AD, Sheppard HM. Unintended CRISPR-Cas9 editing outco- mes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum Genet. 2023;142(6):705–720.

Drummond DA, Wilke CO. The evolutionary consequences of erroneous protein synthesis. Nat Rev Genet. 2009;10(10):715–724.

Ni XY, Zhou ZD, Qiao X. Targeted gene disruption by CRISPR/xCas9 system in Drosophila melanogaster. Arch Insect Biochem Physiol. 2020;104:e21662.

Zirin J, Bosch J, Viswanatha R, Mohr SE, Perrimon N. State-of-the-art CRISPR for in vivo and cell-based studies in Drosophila. Trends Genet. 2021;37(2):111–123.

Sun M, Oulabi I, Chen L. CRISPR/Cas9 Genome Editing System in Drosophila. Adv Tech Biol Med. 2015;S1:3.

Milligan G, Inoue A. Genome Editing Provides New Insights into Receptor-Controlled Sig- nalling Pathways. Trends Pharmacol Sci. 2018;39(5):481–493.

Atanes P, Ruz-Maldonado I, Hawkes R, Liu B, Persaud SJ, Amisten S. Identifying Signalling Pathways Regulated by GPRC5B in beta-Cells by CRISPR-Cas9-Mediated Genome Editing. Cell Physiol Biochem. 2018;45(2):656–666.

Yip HYK, Papa A. Targeting the PI3K/Akt/mTOR Signaling Pathway in Cancer. Mol Cancer. 2020;19(1):100.

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014;4:64.

Nunez JK, Chen J, Pommier GC, Cogan JZ, Replogle JM, Adriaens C, et al. Genome-wi- de programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184(9):2503–2519.e17.

DeWitt MA, Magis W, Bray NL, Wang T, Berman JR, Urbinati F, et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med. 2016;8(360):360ra134.

Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13(6):653–658.

Chen S, Sun H, Miao K, Deng CX. CRISPR-Cas9: from genome editing to cancer research and therapeutic applications. Cell Biosci. 2014;4:62.

Ma L, Hernandez AN, Tajima Y. PD-1/PD-L1 blockade as a novel strategy for cancer immu- notherapy. Cancer Treat Rev. 2020;46:105–112.

Wang F, Wang C, Liu P, Lei C, Hao W, Gao Y, et al. Enhanced rice blast resistance by CRISPR/ Cas9-targeted mutagenesis of the ERF transcription factor gene OsERF922. PLoS One. 2014;9(9):e107335.

Dong OX, Yu S, Jain R, Zhang N, Duong PQ, Butler C, et al. Marker-free carotenoid-en- riched rice generated through targeted gene insertion using CRISPR-Cas9. Nat Commun. 2020;11(1):1178.

Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J. Don’t edit the human germ line. Nature. 2015;519(7544):410–411.

Jasanoff S, Hurlbut JB, Saha K. CRISPR democracy: gene editing and the need for inclusive deliberation. Issues Sci Technol. 2015;32(1):25–32.

Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet. 2016;17(5):300–312.

Simhadri VL, McGill JR, McMahon S, Wang J, Jiang H, Sauna ZE. A transgene-encoded an- tibody delivery platform for suppressing neutralizing antibodies to CRISPR-Cas9. Mol Ther Methods Clin Dev. 2018;10:11–19.

Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-repla- ce genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149– 157.

National Academies of Sciences, Engineering, and Medicine. Human Genome Editing: Scien- ce, Ethics, and Governance. Washington, DC: National Academies Press; 2017.

Cohen J. The untold story of the ‘circle of trust’ behind the world’s first gene-edited babies. Science [Internet]. 2019 [cited 2024 Dec 24]. DOI: 10.1126/science.aaw8360.

Krishnamurthy S, Markus HS. The trials of He Jiankui: A call for increased governance of human genome editing. J Med Ethics. 2020;46(7):471–473.

Cyranoski D. What next for CRISPR babies? Nature. 2019;566(7745):440–442.

Coller BS. Ethics of Human Genome Editing. Annu Rev Med. 2019;70:289–305.

Bawa AS, Anilakumar KR. Genetically modified foods: safety, risks and public concerns-a review. J Food Sci Technol. 2013;50(6):1035–1046.

Ayanoglu FB, Elcin AE, Elcin YM. Bioethical issues in genome editing by CRISPR-Cas9 tech- nology. Turk J Biol. 2020;44(2):110–120.

Rubeis G, Steger F. Risks and benefits of human germline genome editing: An ethical analysis. Asian Bioeth Rev. 2018;10(2):133–141.

Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet. 2016;17(5):300–312.

Rabaan AA, AlSaihati H, Bukhamsin R, Bakhrebah MA, Nassar MS, Alsaleh AA, et al. App- lication of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction. Curr Oncol. 2023;30(2):1954–1976.

Stefanoudakis D, Kathuria-Prakash N, Sun AW, Abel M, Drolen CE, Ashbaugh C, et al. The Po- tential Revolution of Cancer Treatment with CRISPR Technology. Cancers. 2023;15(6):1813.

Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022;22:259–279.

Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38(7):870–874.

Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.

Ledford H. Nobel Prize for CRISPR honours two great collaborators. Nature. 2020;586(7829):195–196.

Cyranoski D. China CRISPR twins: A commentary on the global and ethical implications. Nature. 2019;574(7778):467–470.

Alonso M, Savulescu J. He Jiankui gene-editing experiment and the non-identity problem. Bioethics. 2021;35(6):563–573.

Greely HT. CRISPR babies: human germline genome editing in the He Jiankui affair. J Law Biosci. 2019;6(1):111–183.

Raposo VL. The First Chinese Edited Babies: A Leap of Faith in Science. JBRA Assist Reprod. 2019;23(3):197–199.

BBC News. China jails gene-edited babies scientist for three years [Internet]. 2019 Dec 30 [cited 2024 Dec 24]. Available from: https://www.bbc.com/news

Congressional Research Service. CRISPR gene editing: Applications, challenges, and regulati- on. Washington, DC: CRS; 2023.

Waltz E. Gene-edited CRISPR mushroom escapes US regulation. Nature. 2016;532:293.

Coats DR. Worldwide threat assessment of the US intelligence community. Washington, DC: Office of the Director of National Intelligence; 2018.

Cyranoski D, Ledford H. Genome-edited baby claim provokes international outcry. Nature. 2018;563(7733):607–608.

Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326(5959):1509–1512.

Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science. 2009;326(5959):1501.

Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011;29(2):143–148.